D.C. hospital first to receive Joint Commission/AABB blood transfusion certification

The Joint Commission and the AABB (formerly the American Association of Blood Banks) has awarded its first Patient Blood Management Certification to MedStar-Georgetown University Hospital in Washington, D.C.

According to the commission, the certification reflects “an evidence-based approach” to reducing unnecessary use of one of the most common procedure for an admitted patient—a blood transfusion. The Joint Commission has said “nearly 11 percent of all hospital stays with a procedure include transfusion,” with hospitals spending more than $3 billion on transfusion, even though it found that half of red blood cell transfusions are later found to be inappropriate.

“AABB commends MedStar Georgetown University Hospital for being the first U.S. institution to earn a patient blood management certification,” AABB President, Zbigniew Szczepiorkowski, MD, PhD, said in a statement. “Implementing a comprehensive patient blood management program helps institutions provide a higher quality of care to patients by avoiding blood loss, minimizing unnecessary blood transfusions and conserving blood for patients who actually benefit from transfusions.”

Onsite reviews for the certification last one day, according to program’s process management guide. Hospitals will need to be Joint Commission-certified to be eligible. AABB-accreditation is not a prerequisite, though for those facilities, an AABB surveyor will be involved in the review along with a Joint Commission inspector.

MedStar Georgetown is a 609-bed nonprofit acute care hospital. Its certification, along with any hospitals who meet the same standards in the future, will last two years.

“This distinction is a testament to the hard work of our associates who promote patient safety through a comprehensive blood management program that uses internationally accepted systems and techniques,” said Michael C. Sachtleben, president, MedStar Georgetown University Hospital. “Our patients benefit from this innovative certification that recognizes our commitment to continuously improve our processes and procedures when it comes to patient-centered blood management and services.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.